Antibiotic Cycling: Can Rotating ICU Drugs Curb

Why consider antibiotic cycling after COVID-19?

The CDC's COVID-19 review, updated in February 2025, reports that hospital-onset resistant infections and associated deaths increased by at least 15% from 2019 to 2020 across seven pathogens. These are historical findings, not estimates for October 2026. Longer hospital stays, greater use of invasive devices and disrupted infection prevention contributed to the setback. [CDC pandemic review](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).

Antibiotic cycling changes a ward's preferred antibiotic group on a schedule. Its rationale is to interrupt prolonged exposure to one group and the selective advantage that exposure gives resistant bacteria. This is a prescribing policy for a hospital unit; it does not mean automatically switching an individual patient's treatment whenever the calendar changes. The approach is described in the [IDSA/SHEA stewardship guideline](https://www.idsociety.org/practice-guideline/implementing-an-ASP/).

What did the randomized antibiotic-cycling trial find?

Published in The Lancet Infectious Diseases in 2018, the trial compared changing preferred antibiotic groups every six weeks with changing preference for each consecutively treated patient, called mixing. Participating ICUs crossed over between strategies. The options included cephalosporins, piperacillin-tazobactam and carbapenems. [Trial report](https://pubmed.ncbi.nlm.nih.gov/29396000/).

Resistant Gram-negative bacteria were detected in 23% of surveyed patients during cycling and 22% during mixing, without a statistically significant difference. The endpoint measured bacterial carriage on screening swabs, which does not necessarily mean active infection. The comparison establishes no demonstrated advantage for cycling over mixing; it does not establish that either strategy outperforms usual care. This research also predates COVID-19. [Trial findings and methods](https://pubmed.ncbi.nlm.nih.gov/29396000/).

How should hospitals protect antibiotic effectiveness?

The 2016 IDSA/SHEA guideline suggests against antibiotic cycling as a stewardship strategy, grading that recommendation as weak because the supporting evidence was low quality. It recommends treatment durations matched to the shortest effective course and supports local resistance summaries to guide initial prescribing. These measures address whether a drug is appropriate for the infection and patient. [IDSA/SHEA recommendations](https://www.idsociety.org/practice-guideline/implementing-an-ASP/).

CDC's hospital stewardship framework emphasizes accountable clinical leadership, pharmacy expertise, prescribing interventions and measurement of antibiotic use and outcomes. For a hospital evaluating a rotation policy, the practical implication is to assess treatment effectiveness and resistance alongside prescribing patterns: changing which drug is used most often is not, by itself, evidence of better care. [CDC hospital stewardship framework](https://www.cdc.gov/antibiotic-use/hcp/core-elements/hospital.html).

Prescribing improvements also need functioning infection prevention. The CDC's pandemic findings identify hand hygiene, equipment cleaning and appropriate protective equipment as essential defenses. A change in antibiotic policy cannot replace measures that prevent resistant organisms from spreading between patients. [CDC pandemic review](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).